MedTrace Logo

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

NCT03476798 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2024-02-15

Study results available
· View outcomes & findings →

Summary

This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.

Conditions

Interventions

DRUG

Rucaparib

Rucaparib 600mg PO BID daily

DRUG

Bevacizumab

Bevacizumab 15mg/kg IV on day 1 of each cycle

Sponsors & Collaborators

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Kathleen Moore, MD · Obstetrics and Gynecology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-29
Primary Completion
2020-05-12
Completion
2023-09-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476798 on ClinicalTrials.gov